Executive summary: US Patent 10,597,400 is a US-method-of-treatment patent focused on orally dosed, once-daily 15 mg of the free-base active (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, in moderately to severely active rheumatoid arthritis (RA), with efficacy endpoints defined at week 12 (ACR70, DAS28(CRP), CDAI). Claims also narrow to a specific solid form: free base crystalline hemihydrate, Freebase Hydrate Form C, with defined XRPD peaks. The practical claim scope is therefore: (1) dose-and-schedule and (2) week-12 responder definitions, plus (3) solid-state form for the hemihydrate-subset claims. This structure materially affects design-around risk, generic/biosimilar entry timing, and method-claim exposure for carve-outs.
H1: US Patent 10,597,400 Scope and Claims Analysis (rheumatoid arthritis oral 15 mg hemihydrate Form C)
What does US Patent 10,597,400 claim in plain terms?
Answer: It claims specific methods of treating moderate-to-severe RA by orally administering once daily a defined chemical at an amount sufficient to deliver 15 mg per unit of the free-base equivalent, where the treated subject meets a defined week-12 clinical endpoint (ACR70, DAS28(CRP), or CDAI). A subset further limits the drug substance to a specific crystalline hemihydrate solid form (“Freebase Hydrate Form C”) with XRPD peak locations.
Claim architecture (how infringement is structured)
The claims are grouped into three layers:
-
Core active + dosing regimen + RA indication
- Active: the exact (3S,4R) stereochemically defined compound.
- Route: oral.
- Schedule: once daily.
- Unit strength: amount sufficient to deliver 15 mg per unit dosage form of free base equivalent.
- Disease: moderately to severely active RA.
-
Clinical responder requirement at week 12
- Claim 1: ACR70 by week 12
- Claim 9: DAS28(CRP) < 2.6 by week 12
- Claim 17: CDAI ≤ 2.8 by week 12
-
Material/solid form limitation (for hemihydrate subset claims)
- Claims 6–8 (and 14–16, 22–24 depending on the method wrapper)
- Drug substance must be:
- “free base crystalline hemihydrate”
- specifically “Freebase Hydrate Form C”
- with XRPD peaks at 13.4 ± 0.2, 15.1 ± 0.2, 21.7 ± 0.2 degrees 2θ at ~25°C with Cu Kα1 (as stated in the claims).
Dependent claim narrowing (additional patient and use constraints)
The dependent claims narrow the treated population and prior therapy exposure, including:
- Adult subject (claims 2, 10, 18)
- Inadequate response or intolerance to one or more DMARDs (claims 3, 11, 19)
- Inadequate response/intolerance to:
- methotrexate (claims 4, 12, 20)
- anti-TNF biologic agent (claims 5, 13, 21)
These dependent constraints matter for method-of-treatment enforcement because they condition the infringing “subject in need thereof” class.
What is the key independent claim scope (claim 1 vs claim 9 vs claim 17)?
Answer: The independent method claims differ by the week-12 efficacy endpoint required for the patient. That endpoint selection is the dominant technical and litigation lever because it ties infringement to specific measured outcomes.
Claim 1 (ACR70 responder at week 12)
- Oral, once daily dosing of the defined free-base compound to deliver 15 mg per unit.
- Moderately to severely active RA.
- Infringing method occurs when the treated subject achieves ACR70 by week twelve.
Risk implication: To infringe claim 1, evidence must establish both regimen compliance and that the real-world treated subject meets the ACR70 criterion by week 12. This can create practical evidentiary burdens in litigation.
Claim 9 (DAS28(CRP) responder threshold at week 12)
- Same dosing regimen and RA indication.
- Endpoint: DAS28(CRP) < 2.6 by week 12.
Risk implication: DAS28(CRP) is a composite measure with CRP input. Endpoint proof depends on measurement definitions and timing consistency.
Claim 17 (CDAI threshold at week 12)
- Same dosing regimen and RA indication.
- Endpoint: CDAI ≤ 2.8 by week 12.
Risk implication: CDAI is non-lab-based in its computation except for physician/patient components. Claim proof depends heavily on recorded indices.
How the three independent claims interact
Because each claims the same core regimen and indication but differs on the week-12 endpoint, the patent covers multiple “responder” operational definitions. A competitor could attempt to argue their clinical evidence or labeling does not target the threshold, but infringement for method claims still typically turns on actual patient outcomes in practice.
What formulations are protected by US 10,597,400 (Freebase Hydrate Form C, hemihydrate XRPD)?
Answer: Claims 6–8 (and corresponding hemihydrate subsets embedded in claims 14–16 and 22–24) protect methods when the administered active is specifically the free base crystalline hemihydrate, identified as Freebase Hydrate Form C by an XRPD fingerprint.
Solid-state limitation details
- Material: “free base crystalline hemihydrate”
- Specific polymorph/solvate/hydrate: “Freebase Hydrate Form C”
- XRPD constraint: peaks at
- 13.4 ± 0.2°
- 15.1 ± 0.2°
- 21.7 ± 0.2°
- Measurement: about 25°C, with monochromatic Kα1 radiation (as stated in the claims).
Scope consequence: “hemihydrate subset” vs “non-hemihydrate wrapper”
Only the claims that recite the hemihydrate and Form C XRPD are formulation-limited. Claims 1/9/17 (as independent statements of method) are not explicitly limited to a specific hydrate form in the claim text you provided.
Business impact: If a competitor markets an alternative hydrate form while using the same dosage regimen and achieves the same week-12 endpoint, they may still face exposure under the endpoint/dose claims that lack the solid-form restriction. Conversely, designing to avoid the hemihydrate Form C can reduce exposure for the XRPD-limited claims.
When does US Patent 10,597,400 expire, and when can exclusivity end?
Answer: Not determinable from the claim text alone. Patent expiration depends on the application and patent filing dates, priority chain, and any adjustment; exclusivity depends on the related FDA approval history and Orange Book/NCE status.
No complete expiration timeline can be produced without bibliographic data for US 10,597,400 and the specific FDA product linked to it.
What is the Orange Book status of the drug related to US 10,597,400?
Answer: Not determinable from the claims alone. Orange Book listing status requires the specific marketed product name (brand/generic/manufacturer) tied to the active and the exact strength/formulation.
No Orange Book conclusion is provided without the product/holder identifiers.
How strong is the patent estate based on the claim scope you provided?
Answer: Strength is moderate-to-high on dose-and-endpoint and solid-form subsets because the claims define multiple technical gating features. It is also constrained by proving endpoint attainment at week 12 and by the likelihood that infringement will be litigated around real-world outcome evidence, study data, and labeling.
Strength factors embedded in the claim language
- Specific active identity and stereochemistry
- Limits the covered chemical space tightly.
- Specific administration regimen
- Specific unit strength
- 15 mg per unit dosage form, and free-base equivalent delivery.
- Specific RA severity class
- “moderately to severely active” RA.
- Specific clinical endpoints and timing
- ACR70 at week 12
- DAS28(CRP) <2.6 at week 12
- CDAI ≤2.8 at week 12
- XRPD-defined solid form (for Form C claims)
- Provides a concrete testable identity for the drug substance used.
Weakness or friction points for enforcement
- Outcome conditioning
- Method claims conditioned on achieving specific indices by a fixed time can be harder to prove for generics and for “off-label” populations.
- Clinical measurement dependencies
- Endpoints rely on standardized evaluation and consistent protocol definitions.
- Patient-criteria dependencies (dependent claims)
- DMARD / methotrexate / anti-TNF inadequate response or intolerance is a conditional population definition, limiting enforcement to the described subject class when those dependent claims are asserted.
How could a generic or competitor design around US 10,597,400?
Answer: Design-around is most viable by targeting the claim “gates”: dose/schedule, endpoint/timing evidence, and solid-state identity.
Potential design-around pathways (claim-gate analysis)
-
Change dose or unit strength delivery logic
- Claims require delivery sufficient to give 15 mg free base equivalent per unit dosage form, once daily.
- A different strength regimen (and associated method-of-treatment regimen) can be argued to avoid the “amount sufficient to deliver 15 mg per unit dosage form” limitation.
-
Avoid the specific responder thresholds at week 12
- If a competitor uses a different dosing strategy or patient selection such that the method practiced does not meet:
- ACR70 by week 12, or
- DAS28(CRP) < 2.6 by week 12, or
- CDAI ≤ 2.8 by week 12,
then literal infringement is less likely for those independent claims.
- In practice, this is difficult because clinical outcomes often overlap, and labels/study designs can establish meeting thresholds.
-
Use a different hydrate form than “Freebase Hydrate Form C”
- For hemihydrate subset claims, selecting a different hydrate/solvate form that does not match the XRPD peaks can reduce exposure.
- This does not immunize against endpoint-only claims lacking the solid form limitation.
-
Target populations not matching dependent subject criteria
- If the accused practice is limited to populations that do not meet:
- inadequate response or intolerance to DMARDs,
- methotrexate,
- or anti-TNF biologics,
then dependent-claim enforcement is narrowed.
What patent litigation risks exist from US 10,597,400?
Answer: Based strictly on claim structure, the most credible litigation theory is method-of-treatment infringement tied to:
- the 15 mg once-daily regimen,
- real-world treated RA patients with DMARD/MTX/anti-TNF inadequate response (if dependent claims are asserted),
- and documented week-12 responder outcomes, and in a subset, the XRPD identity of the hemihydrate Form C.
But the existence of active litigation, Paragraph IV notices, settlement terms, or court rulings cannot be determined from the claims you provided.
Which companies are likely implicated by US 10,597,400?
Answer: Not determinable from the claims alone. Company identification requires the US application assignee, patent prosecution data, and the marketed product’s label holder and manufacturing chain.
How does US 10,597,400 compare with typical RA method patents?
Answer: It is tighter than many broad RA method-of-treatment claims because it adds three high-specificity constraints that often do not coexist:
- Exact dose strength per unit (15 mg free base equivalent)
- Specific week-12 responder thresholds with distinct scoring systems
- A defined crystalline hydrate Form C identity via XRPD peaks
This combination narrows the covered practices, but when practiced, can increase infringement clarity.
Key claim-by-claim scope map (for litigation and freedom-to-operate triage)
| Claim |
Endpoint / Gate |
Dosing gate |
Solid-state gate |
Practical infringement hinge |
| 1 |
ACR70 by week 12 |
Oral once daily; deliver 15 mg free base eq/unit |
None stated |
Patient meets ACR70 at week 12 under regimen |
| 2-5 |
Adult; DMARD/MTX/anti-TNF inadequate response or intolerance |
Inherits claim 1 |
None |
Only if subject criteria match |
| 6-8 |
Same as claim 1 |
Inherits claim 1 |
Free base crystalline hemihydrate; “Form C” |
XRPD identification plus dosing and ACR70 |
| 9 |
DAS28(CRP) < 2.6 by week 12 |
Same dosing gate (15 mg) |
None stated |
Patient meets DAS28(CRP) threshold at week 12 |
| 10-13 |
Adult; DMARD/MTX/anti-TNF inadequate response or intolerance |
Inherits claim 9 |
None |
Dependent population narrowing |
| 14-16 |
Same as claim 9 |
Same as claim 9 |
Free base crystalline hemihydrate; Form C; XRPD peaks |
XRPD identity plus week-12 DAS28(CRP) |
| 17 |
CDAI ≤ 2.8 by week 12 |
Same dosing gate (15 mg) |
None stated |
Patient meets CDAI threshold at week 12 |
| 18-21 |
Adult; DMARD/MTX/anti-TNF inadequate response or intolerance |
Inherits claim 17 |
None |
Dependent population narrowing |
| 22-24 |
Same as claim 17 |
Same as claim 17 |
Free base crystalline hemihydrate; Form C; XRPD peaks |
XRPD identity plus week-12 CDAI |
Key Takeaways
- US Patent 10,597,400 is built around method-of-treatment claims for moderately to severely active RA with a once-daily oral 15 mg free-base regimen and week-12 responder endpoints (ACR70, DAS28(CRP), CDAI).
- A defined portion of the claim set adds a solid-state limiter: Freebase Hydrate Form C identified by XRPD peaks at 13.4 ± 0.2°, 15.1 ± 0.2°, 21.7 ± 0.2° (2θ) at about 25°C.
- Enforcement risk concentrates on practices that both follow the regimen and produce documented week-12 score thresholds, with additional narrowing if dependent population criteria (adult, DMARD/MTX/anti-TNF inadequate response or intolerance) are asserted.
- Design-around most plausibly targets (i) strength/dosing, (ii) endpoint/timing alignment, and/or (iii) selection of a non-Form C hydrate to avoid XRPD-limited claims.
FAQs
-
Does US 10,597,400 protect only the hemihydrate Form C solid state?
No. The hemihydrate Form C limitation appears only in the subset claims that explicitly require it by XRPD. Other endpoint/dose claims you listed are not, on their face, limited to Form C.
-
What is the highest-infringement-risk scenario for an oral once-daily RA product?
A product using the exact active identity plus a once-daily dosing scheme delivering 15 mg per unit and producing treated subjects who meet the specified week-12 responder thresholds.
-
Can a different hydrate form avoid all claims?
It can potentially avoid the XRPD-limited Form C claims, but it does not automatically avoid endpoint-only method claims that lack the solid-state limitation.
-
How do the dependent claims narrow the eligible patient class?
They require adult status and inadequate response or intolerance to DMARDs, including specific subsets for methotrexate and anti-TNF biologics.
-
Why do the claims include week-12 thresholds like ACR70 and DAS28(CRP)?
They make infringement tethered to a specific treatment outcome measured by standard RA indices at a fixed timepoint, which increases both technical specificity and evidentiary focus in enforcement.
References
- US Patent No. 10,597,400 (claims as provided).
